最懂炒股的医疗公司？九安医疗：主业躺平，投资躺赢，市值躺枪

Core Viewpoint - Jiuan Medical (002432.SZ) is expected to achieve a net profit of 2.02 billion to 2.35 billion yuan in 2025, representing a year-on-year growth of 21.05% to 40.83% primarily driven by strong performance in asset management business [1][13]. Financial Performance - For the first three quarters of 2025, Jiuan Medical reported revenue of 1.069 billion yuan, but net profit reached 1.589 billion yuan, with total operating costs exceeding revenue at 1.276 billion yuan [3][15]. - Investment income for the same period was 562 million yuan, and fair value changes contributed 1.251 billion yuan, totaling over 1.8 billion yuan in income from these sources [3][15]. - The company’s net profit attributable to shareholders is projected to grow by 21.05% to 40.83% compared to the previous year [2][14]. Asset Management - As of the end of Q3 2025, Jiuan Medical held trading financial assets worth 10.362 billion yuan, primarily in wealth management products, along with fixed-income securities and equity investments totaling 13.877 billion yuan [4][16]. - The total assets under management reached 24.122 billion yuan, indicating a significant contribution from asset management to overall profitability [5][18]. Product Performance - The iHealth product line, which includes smart medical devices, has seen a significant decline in revenue, with a 50% drop in the first half of 2025 compared to the previous year [8][21]. - Overall revenue from the iHealth series decreased by 49% in the first three quarters of 2025 [9][20]. Market Position - Jiuan Medical's price-to-book (PB) ratio is currently at 0.89, indicating it is trading below its book value [11][23]. - The company has substantial cash-like assets totaling 27.6 billion yuan, with short-term borrowings of only 2.334 billion yuan, suggesting a strong liquidity position [11][23].